| Item Type | Name |
|
Concept
|
Survival Analysis
|
|
Concept
|
Survival Rate
|
|
Concept
|
Cell Survival
|
|
Concept
|
Disease-Free Survival
|
|
Academic Article
|
Phase II trial of topotecan administered as a 21-day continuous infusion in previously untreated patients with stage IIIB and IV non-small-cell lung cancer.
|
|
Academic Article
|
Edatrexate (10-ethyl-deaza-aminopterin) (NSC #626715) with or without leucovorin rescue for malignant mesothelioma. Sequential phase II trials by the cancer and leukemia group B.
|
|
Academic Article
|
Phase II study of pemetrexed with and without folic acid and vitamin B12 as front-line therapy in malignant pleural mesothelioma.
|
|
Academic Article
|
The pemetrexed/gemcitabine combination in pancreatic cancer.
|
|
Academic Article
|
Phase II study of flavopiridol in patients with advanced colorectal cancer.
|
|
Academic Article
|
Capecitabine in malignant mesothelioma: a phase II trial by the Cancer and Leukemia Group B (39807).
|
|
Academic Article
|
Weekly, high-dose paclitaxel in advanced lung carcinoma: a phase II study with pharmacokinetics by the Cancer and Leukemia Group B.
|
|
Academic Article
|
Phase I/II trial of gefitinib and oxaliplatin in patients with advanced colorectal cancer.
|
|
Academic Article
|
A phase III trial of pemetrexed plus gemcitabine versus gemcitabine in patients with unresectable or metastatic pancreatic cancer.
|
|
Academic Article
|
9-Aminocamptothecin (9-AC) given as a 120-hour continuous infusion in patients with advanced adenocarcinomas of the stomach and gastroesophageal junction: A phase II trial of the University of Chicago phase II consortium.
|
|
Academic Article
|
Response to the methylation inhibitor dihydro-5-azacytidine in mesothelioma is not associated with methylation of p16INK4a: results of cancer and leukemia group B 159904.
|
|
Academic Article
|
Protein kinase C beta in malignant pleural mesothelioma.
|
|
Academic Article
|
A phase II study of lapatinib in patients with advanced biliary tree and hepatocellular cancer.
|
|
Academic Article
|
Phase II trial of pemetrexed and gemcitabine in chemotherapy-naive malignant pleural mesothelioma.
|
|
Academic Article
|
Antiangiogenic therapies for mesothelioma.
|
|
Academic Article
|
Phase II trial of bevacizumab plus gemcitabine in patients with advanced pancreatic cancer.
|
|
Academic Article
|
Randomized phase II study of gemcitabine administered at a fixed dose rate or in combination with cisplatin, docetaxel, or irinotecan in patients with metastatic pancreatic cancer: CALGB 89904.
|
|
Academic Article
|
A Cancer and Leukemia Group B phase II study of sunitinib malate in patients with previously treated metastatic pancreatic adenocarcinoma (CALGB 80603).
|
|
Academic Article
|
Gemcitabine plus sorafenib in patients with advanced pancreatic cancer: a phase II trial of the University of Chicago Phase II Consortium.
|
|
Academic Article
|
Phase I and pharmacokinetic study of erlotinib for solid tumors in patients with hepatic or renal dysfunction: CALGB 60101.
|
|
Academic Article
|
Preclinical studies of the proteasome inhibitor bortezomib in malignant pleural mesothelioma.
|
|
Academic Article
|
Cetuximab is associated with excessive toxicity when combined with bevacizumab Plus mFOLFOX6 in metastatic colorectal carcinoma.
|
|
Academic Article
|
A multicenter phase II study of cisplatin, pemetrexed, and bevacizumab in patients with advanced malignant mesothelioma.
|
|
Academic Article
|
Erlotinib plus bevacizumab in previously treated patients with malignant pleural mesothelioma.
|
|
Academic Article
|
Irinotecan for malignant mesothelioma A phase II trial by the Cancer and Leukemia Group B.
|
|
Academic Article
|
A phase II study of sorafenib in malignant mesothelioma: results of Cancer and Leukemia Group B 30307.
|
|
Academic Article
|
A genome-wide association study of overall survival in pancreatic cancer patients treated with gemcitabine in CALGB 80303.
|
|
Academic Article
|
Vatalanib in malignant mesothelioma: a phase II trial by the Cancer and Leukemia Group B (CALGB 30107).
|
|
Academic Article
|
Optimization of response classification criteria for patients with malignant pleural mesothelioma.
|
|
Academic Article
|
Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303).
|
|
Academic Article
|
Does health-related quality of life improve for advanced pancreatic cancer patients who respond to gemcitabine? Analysis of a randomized phase III trial of the cancer and leukemia group B (CALGB 80303).
|
|
Academic Article
|
Phase II study of dasatinib in patients with previously treated malignant mesothelioma (cancer and leukemia group B 30601): a brief report.
|
|
Academic Article
|
A randomized, placebo-controlled phase 2 study of ganitumab (AMG 479) or conatumumab (AMG 655) in combination with gemcitabine in patients with metastatic pancreatic cancer.
|
|
Academic Article
|
A Phase II trial of fixed dose rate gemcitabine in patients with advanced biliary tree carcinoma.
|
|
Academic Article
|
Gefitinib in patients with malignant mesothelioma: a phase II study by the Cancer and Leukemia Group B.
|
|
Academic Article
|
A phase II prospective multi-institutional trial of adjuvant active specific immunotherapy following curative resection of colorectal cancer hepatic metastases: cancer and leukemia group B study 89903.
|
|
Academic Article
|
Arsenic trioxide in patients with adenocarcinoma of the pancreas refractory to gemcitabine: a phase II trial of the University of Chicago Phase II Consortium.
|
|
Academic Article
|
Axitinib plus gemcitabine versus placebo plus gemcitabine in patients with advanced pancreatic adenocarcinoma: a double-blind randomised phase 3 study.
|
|
Academic Article
|
Multicenter, double-blind, placebo-controlled, randomized phase II trial of gemcitabine/cisplatin plus bevacizumab or placebo in patients with malignant mesothelioma.
|
|
Academic Article
|
Putative predictive biomarkers of survival in patients with metastatic pancreatic adenocarcinoma treated with gemcitabine and ganitumab, an IGF1R inhibitor.
|
|
Academic Article
|
Lung volume measurements as a surrogate marker for patient response in malignant pleural mesothelioma.
|
|
Academic Article
|
25-Hydroxyvitamin D levels and survival in advanced pancreatic cancer: findings from CALGB 80303 (Alliance).
|
|
Academic Article
|
Multicenter Phase II Trial of Temsirolimus and Bevacizumab in Pancreatic Neuroendocrine Tumors.
|
|
Academic Article
|
Impact of physical activity after cancer diagnosis on survival in patients with recurrent colon cancer: Findings from CALGB 89803/Alliance.
|
|
Academic Article
|
The Vulnerable Elders Survey-13 predicts mortality in older adults with later-stage colorectal cancer receiving chemotherapy: a prospective pilot study.
|
|
Academic Article
|
Sugar-sweetened beverage intake and cancer recurrence and survival in CALGB 89803 (Alliance).
|
|
Academic Article
|
Extended Pleurectomy and Decortication for Malignant Pleural Mesothelioma Is an Effective and Safe Cytoreductive Surgery in the Elderly.
|
|
Academic Article
|
Randomized Phase Ib/II Study of Gemcitabine Plus Placebo or Vismodegib, a Hedgehog Pathway Inhibitor, in Patients With Metastatic Pancreatic Cancer.
|
|
Academic Article
|
Specimen weight and volume: important predictors of survival in malignant pleural mesothelioma.
|
|
Academic Article
|
Preoperative Modified FOLFIRINOX Treatment Followed by Capecitabine-Based Chemoradiation for Borderline Resectable Pancreatic Cancer: Alliance for Clinical Trials in Oncology Trial A021101.
|
|
Academic Article
|
A Multicenter Study of Volumetric Computed Tomography for Staging Malignant Pleural Mesothelioma.
|
|
Academic Article
|
Amount of Epithelioid Differentiation Is a Predictor of Survival in Malignant Pleural Mesothelioma.
|
|
Academic Article
|
Validation of Progression-Free Survival as a Surrogate Endpoint for Overall Survival in Malignant Mesothelioma: Analysis of Cancer and Leukemia Group B and North Central Cancer Treatment Group (Alliance) Trials.
|
|
Academic Article
|
Early hypertension (HTN) as a potential pharmacodynamic (PD) marker for survival in pancreatic cancer (PC) patients (pts) treated with bevacizumab (B) and gemcitabine (G).
|
|
Academic Article
|
Overall survival and clinical characteristics of BRCA mutation carriers with stage I/II pancreatic cancer.
|
|
Academic Article
|
Predicted vitamin D status and colon cancer recurrence and mortality in CALGB 89803 (Alliance).
|
|
Academic Article
|
A phase II study of a human anti-PDGFRa monoclonal antibody (olaratumab, IMC-3G3) in previously treated patients with metastatic gastrointestinal stromal tumors.
|
|
Academic Article
|
The impact of changes in radiographic sarcopenia on overall survival in older adults undergoing different treatment pathways for pancreatic cancer.
|
|
Academic Article
|
The vitamin D receptor gene as a determinant of survival in pancreatic cancer patients: Genomic analysis and experimental validation.
|
|
Academic Article
|
Association of Survival With Adherence to the American Cancer Society Nutrition and Physical Activity Guidelines for Cancer Survivors After Colon Cancer Diagnosis: The CALGB 89803/Alliance Trial.
|
|
Academic Article
|
Treatment of Malignant Pleural Mesothelioma: American Society of Clinical Oncology Clinical Practice Guideline.
|
|
Academic Article
|
Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial.
|
|
Academic Article
|
Nut Consumption and Survival in Patients With Stage III Colon Cancer: Results From CALGB 89803 (Alliance).
|
|
Academic Article
|
Marine ?-3 Polyunsaturated Fatty Acid and Fish Intake after Colon Cancer Diagnosis and Survival: CALGB 89803 (Alliance).
|
|
Academic Article
|
Phase 1 trial evaluating cisplatin, gemcitabine, and veliparib in 2 patient cohorts: Germline BRCA mutation carriers and wild-type BRCA pancreatic ductal adenocarcinoma.
|
|
Academic Article
|
Correlation of patient survival with clinical tumor measurements in malignant pleural mesothelioma.
|
|
Academic Article
|
A UGT1A1 genotype-guided dosing study of modified FOLFIRINOX in previously untreated patients with advanced gastrointestinal malignancies.
|
|
Academic Article
|
Dietary Insulin Load and Cancer Recurrence and Survival in Patients With Stage III Colon Cancer: Findings From CALGB 89803 (Alliance).
|
|
Academic Article
|
Inherited predisposition to malignant mesothelioma and overall survival following platinum chemotherapy.
|
|
Academic Article
|
Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer.
|
|
Academic Article
|
Clinical Response of Live-Attenuated, Listeria monocytogenes Expressing Mesothelin (CRS-207) with Chemotherapy in Patients with Malignant Pleural Mesothelioma.
|
|
Academic Article
|
Health-related quality of life in patients with a germline BRCA mutation and metastatic pancreatic cancer receiving maintenance olaparib.
|
|
Academic Article
|
First-in-Human, Multicenter, Phase I Dose-Escalation and Expansion Study of Anti-Mesothelin Antibody-Drug Conjugate Anetumab Ravtansine in Advanced or Metastatic Solid Tumors.
|
|
Academic Article
|
The Diet of Higher Insulinemic Potential Is Not Associated with Worse Survival in Patients with Stage III Colon Cancer (Alliance).
|
|
Academic Article
|
Randomized Study of Maintenance Pemetrexed Versus Observation for Treatment of Malignant Pleural Mesothelioma: CALGB 30901.
|
|
Academic Article
|
Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study.
|
|
Academic Article
|
Malignant peritoneal mesothelioma: prognostic significance of clinical and pathologic parameters and validation of a nuclear-grading system in a multi-institutional series of 225 cases.
|
|
Academic Article
|
Personalized Antibodies for Gastroesophageal Adenocarcinoma (PANGEA): A Phase II Study Evaluating an Individualized Treatment Strategy for Metastatic Disease.
|
|
Academic Article
|
Phase I study of ABBV-428, a mesothelin-CD40 bispecific, in patients with advanced solid tumors.
|
|
Academic Article
|
Race, Income, and Survival in Stage III Colon Cancer: CALGB 89803 (Alliance).
|
|
Academic Article
|
Genome-wide association studies of survival in 1520 cancer patients treated with bevacizumab-containing regimens.
|
|
Academic Article
|
Durvalumab with platinum-pemetrexed for unresectable pleural mesothelioma: survival, genomic and immunologic analyses from the phase 2 PrE0505 trial.
|
|
Academic Article
|
Diet- and Lifestyle-Based Prediction Models to Estimate Cancer Recurrence and Death in Patients With Stage III Colon Cancer (CALGB 89803/Alliance).
|
|
Academic Article
|
Marital Status, Living Arrangement, and Cancer Recurrence and Survival in Patients with Stage III Colon Cancer: Findings from CALGB 89803 (Alliance).
|
|
Academic Article
|
Overall Survival Results From the POLO Trial: A Phase III Study of Active Maintenance Olaparib Versus Placebo for Germline BRCA-Mutated Metastatic Pancreatic Cancer.
|